Clinical Trial Update: Treat-to-target With Secukinumab in Axial Spondyloarthritis [Phase 4]

View source ↗

Summary

A Phase 4 trial update evaluating treat-to-target strategy with secukinumab in axial spondyloarthritis and ankylosing spondylitis is ongoing, status currently u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Axial Spondyloarthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Professor Mikkel Østergaard | Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis | Phase 4 | Status: UNKNOWN